New insights into the biology of schizophrenia through the mechanism of action of clozapine

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
N BrunelloG Racagni

Abstract

Many studies have detected in the brain of schizophrenic patients various morphological and structural abnormalities in various regions and in particular in the cortical and limbic areas. These abnormalities might in part result from neurodevelopmental disturbances suggesting that schizophrenia might have organic causes. These abnormalities may be the primary event in schizophrenia and be responsible for altered dopaminergic, but not only dopaminergic, neurotransmission in these regions. If schizophrenia is in some way strictly related to brain morphological abnormalities it becomes hard to believe that a curative treatment will ever be possible. Considering this scenario, treatment of schizophrenia will be restricted to symptomatic and preventive therapy and therefore, more effective and better tolerated antipsychotics are necessary. The widely used classical antipsychotic drugs present some disadvantages. They do not improve all symptoms of schizophrenia, are not effective in all patients, produce a number of unpleasant and serious, and partly irreversible, motor side effects. The atypical antipsychotic clozapine constitutes a major advance in particular for patients not responding to conventional neuroleptics. To explain the...Continue Reading

Citations

Mar 27, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rakesh KarmacharyaEdgar A Buttner
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Patricia A BroderickYueping Zhou
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Laurent BardinAdrian Newman-Tancredi
May 19, 2011·Clinical Neuropharmacology·Francisco López-Muñoz, Cecilio Álamo
Feb 3, 2004·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Ayman H FanousK S Kendler
Jul 1, 2006·Journal of Neuroscience Research·Taylor Moran-GatesFrank I Tarazi
Feb 14, 2012·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Caroline NothdurfterDan Rujescu
Apr 7, 2005·Brain Research Bulletin·Y LevkovitzS Fennig
May 12, 2005·Schizophrenia Research·Brooke Parrott, Rich Lewine
Sep 29, 2004·Psychiatry Research·Alan I GreenJoseph J Schildkraut
Nov 21, 1998·The European Journal of Neuroscience·P O TremblayC Rouillard
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Guochuan Tsai, Joseph T Coyle
Sep 1, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F I TaraziJ L Neumeyer
Oct 31, 2002·Human Psychopharmacology·Robert D OadesMarie Luise Rao
Dec 17, 2002·Pharmazie in unserer Zeit·Walter E Müller
Mar 21, 2002·Epilepsia·Ulrich Ebert
Sep 28, 1998·The European Journal of Neuroscience·C MaugerF Monsma
Jul 10, 2007·European Journal of Pharmacology·Magdalena ZaniewskaMalgorzata Filip
Oct 27, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Limin HaoEdgar A Buttner
May 9, 2003·The New England Journal of Medicine·Wayne A RayKeith G Meador
Dec 9, 2004·Expert Opinion on Therapeutic Targets·David J Sanger
Aug 2, 2012·Expert Opinion on Pharmacotherapy·Frank I Tarazi, Stephen M Stahl
Jan 1, 1997·Journal of Neural Transmission·E SchulzH Remschmidt
Apr 6, 2017·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Xue-Ting DengXue-Jun Song
Nov 27, 2009·Journal of Psychopharmacology·James M StonePhilip K McGuire
Jan 1, 1997·Journal of Psychopharmacology·J M Vile, P G Strange
Aug 7, 2008·The Annals of Pharmacotherapy·Min YangCynthia A Mascarenas
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ina WeinerInna Gaisler-Salomon
Oct 20, 2017·Expert Opinion on Drug Discovery·Zeyad T Sahli, Frank I Tarazi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here